Immunovia - Discover and develop tools for early diagnosis of cancers

Immunovia walk around the world to raise awareness for pancreatic cancer
July – November 2020

Welcome to join us!

Click to register

Immunovia leads clinical validation studies with > 10,000 subjects recruited at 24 sites from Europe and USA covering the three highest risk groups for pancreatic cancer

Designed to validate IMMray™ PanCan-d, PanFAM-1 is the largest prospective multicenter clinical study for early detection of pancreatic cancer in familial high risk individuals

Immunovia initiated PanDIA-1, the world’s largest study for early detection of pancreatic cancer in the high risk group of new onset diabetic patients

IMMray™ PanCan-d is undergoing evaluation study for diagnosing high risk early symptomatic patients at a treatable stage of pancreatic cancer

IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective studies with 1800 samples

Breakthrough in autoimmune testing – IMMray™ based novel biomarker signature identifies patients with anti-CCP negative rheumatoid arthritis

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

MOVIE
Immunovia and
IMMray™ technology
(10 min)

Press releases

June 30, 2020

Change in the number of shares and votes in Immunovia AB (publ)

June 30, 2020

Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d

June 29, 2020

Immunovia to Present a Satellite Symposium at the European Pancreatic Club (EPC) – International Association of Pancreatology’s (IAP) Annual Meeting July 2, 2020

Financial reports

April 2020

Immunovia AB published the company’s Interim Report Jan-March 2020 on Tuesday, April 28, 2020, at 16.00 p.m. CET.

Immunovia Interim Report Jan-March 2020 (PDF in English)

Immunovia Interim Report Jan-March 2020 (PDF in Swedish)

Financial reports

Calendar

20 August, 2020

Interim report Jan-June 2020

Place: Immunovia website

21 August, 2020

Place: Stockholm, Sweden

3 September, 2020

Pareto Securities’ 11th Annual Health Care Conference

Place: Stockholm, Sweden